We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
WHX Labs Dubai 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mitochondrial Enzyme Breaks Down Nitroglycerin

By Biotechdaily staff writers
Posted on 13 Jun 2002
Investigators have found that the enzyme mitochondrial aldehyde dehydrogenase (mtALDH) is at least partially responsible for the bioactivation of nitroglycerin and is likely the target of nitroglycerin tolerance. Nitroglycerin has been used for more than 130 years for relief of chest pain without a clear knowledge of how it actually works. Furthermore, it was not known why some patients became tolerant to nitroglycerin and ceased to be affected by it.

What has been known is that nitroglycerin must be metabolized to release nitric oxide. However, neither the site of this metabolism nor the enzymes responsible have been identified. Now, a study published online June 4, 2002, in the Proceedings of the National Academy of Sciences describes the discovery of an enzyme that not only breaks down nitroglycerin and releases a nitric-oxide related molecule, but whose action is suppressed in blood vessels made tolerant after repeated doses of nitroglycerin.

The study was conducted by researchers from Duke University (Durham, NC, USA), who isolated a nitrate reductase from macrophage mitochondria that specifically catalyzes the formation of 1,2-glyceryl dinitrate and nitrite from nitroglycerin, leading to production of cGMP and relaxation of vascular smooth muscle both in vitro and in vivo. They identified the enzyme as mitochondrial aldehyde dehydrogenase (mtALDH).

A new approach was taken in this study in that the researchers screened many types of cells for the ability to metabolize nitroglycerin rather than to focus on vascular cells. They found that macrophages were a rich source of this activity. A detailed study of these macrophages led to the finding that the breakdown of nitroglycerin occurred in the mitochondria. Looking then at mitochondria from vascular cells, they found that indeed mtALDH was present and mediated the release of nitric oxide from nitroglycerin.

As to why some patients develop tolerance to nitroglycerin, Dr. Jonathan Stamler, who led the Duke study, explained, "In general, cells do not work as well after being exposed to nitroglycerin. It appears that after several reactions, the enzyme is used up, and over time the mitochondria become totally depleted of active enzyme and are therefore unable to break down nitroglycerin.”

Understanding the molecular mechanism of nitroglycerin bioactivation and tolerance may lead to the design and development of novel nitrovasodilator drugs that do not cause tolerance.



Related Links:
Duke University

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Gold Member
Immunochromatographic Assay
CRYPTO Cassette

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
13 Jun 2002  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
13 Jun 2002  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
13 Jun 2002  |   BioResearch